A Letter From the Guest Editors

A Brighter Future for Patients With Melanoma

Diagnosis, Evaluation, and Surgical Management of Melanoma

Abstract Melanoma accounts for 5.3% of all new cancer diagnoses, with increasing rates over the past 4 decades. Risk factors include multiple nevi, family history, sun exposure, immunosuppression, and environmental exposure. Ongoing pub...

Harnessing the Immune System in the Treatment of Melanoma

Abstract Melanoma has long been considered an immunogenic cancer. Early treatment options for melanoma therapy focused on the use of cytokines as a means of stimulating the immune system; these agents were used as single agents or in co...

BRAF/MEK Inhibition in Melanoma: An Update

Abstract Melanoma accounts for significant mortality, and its incidence continues to rise. Extensive research regarding the molecular basis of melanoma has identified a critical role for the aberrantly activated MAPK pathway in its path...

Mutations Beyond BRAF V600

Abstract Among mutations in melanoma, BRAF V600 mutations have historically attracted the most attention and research. However, NRAS, GNAQ, c-KIT, NF1, and atypical BRAF mutations, although less common, warrant identification and consid...

Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes

Abstract The most common presentation of melanoma is that of a primary skin lesion; however, there is a unique subset of patients who will present with rare and unique clinical circumstances requiring acute attention with respect to dia...

Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma

Abstract Molecularly targeted agents, and notably, the immune checkpoint inhibitors, are now considered standard therapies for the treatment of advanced melanoma and have forever changed the treatment paradigm for this difficult-to-trea...

Drug-Drug Interactions in Melanoma

Abstract Tyrosine kinase inhibitors are indicated for the treatment of a variety of malignancies, but are used commonly in patients with advanced melanoma. Most are also substrates for various efflux transporters, including P-glycoprote...

Appendix